Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S65487 + Azacitidine in Untreated AML Not Eligible for Intensive Treatment
NCT04742101Phase 2Completed
- Sponsor
- Servier
- Start
- Mar 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of VOB560 in acute myeloid leukemia (AML), sponsored by Servier. Primary endpoints: Dose Limiting Toxicity at 4 weeks, Adverse Events and 1 more. Started Mar 2021; status: completed.
02
Drugs
VOB560
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04742101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742101.